Physician profile
Bryce A Ayers
NPI 1689610446
$1,126.85
in general payments reported to CMS, 2019-2025
17 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $99.92 · 2021: $44.37 · 2022: $67.16 · 2023: $394 · 2024: $260 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.91 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.39 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $121.40 | 2019-2020 | |
| Glaxosmithkline, LLC. | $70.21 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $66.40 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $54.71 | 2020-2025 | Wegovy |
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $35.56 | 2024-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $31.97 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $31.56 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.58 | 2024 | Trintellix |
| Pfizer INC. | $29.49 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.17 | 2021 | |
| Exact Sciences Corporation | $17.49 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $16.81 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $15.23 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $14.06 | 2022 | |
| Edwards Lifesciences Corporation | $13.28 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.